ATCC

ATCC and USP Launch First Set of Products to Advance Quality and Reduce Risk in the Development of Biological Therapeutics and Vaccines

Retrieved on: 
Monday, October 30, 2023
A-DNA, Quality control, Safety, Immortalised cell line, DNA, General counsel, Risk, USP, Vaccine, ATCC

MANASSAS, Va. and ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ -- Today, ATCC and U.S. Pharmacopeia (USP), two premier materials management and standards organizations, announced the launch of their first set of joint products to advance the quality control and reduce the risk in the manufacturing of biological therapies and vaccines. This initial set of six products consists of highly characterized and pure genomic DNA (gDNA) from cell lines used in bioproduction that can be used to measure residual host cell DNA in various biotherapeutic products, as required by regulatory authorities. The presence of gDNA is a predominant concern in the development of biological therapies as it can pose a safety risk if it is not removed from the product.

Key Points: 
  • MANASSAS, Va. and ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ -- Today, ATCC and U.S. Pharmacopeia ( USP ), two premier materials management and standards organizations, announced the launch of their first set of joint products to advance the quality control and reduce the risk in the manufacturing of biological therapies and vaccines.
  • The presence of gDNA is a predominant concern in the development of biological therapies as it can pose a safety risk if it is not removed from the product.
  • By focusing on the detection of gDNA, this first set of ATCC and USP products is significant for the future of biological development as it addresses a common concern when it comes to quality and mitigating risk."
  • The first set of products from ATCC and USP allows users to test the drug substance and process intermediates to assess clearance of residual gDNA with analytical reference materials derived from an authenticated cell line.

Globla Primary Cell Culture Industry's Vital Role in Advancing Precision Therapies and Regenerative Medicine Sparks Remarkable Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 26, 2023
Health, Pharmaceutical, Tissue, Cell type, Primary cell culture, COVID-19, ATCC, USD, Regenerative medicine, Process control block, Patient, Organoid, Application, Cell, Drug discovery, Biology, Growth, Virus, Reagent, Wound healing, Vaccine

Primary cell culture, offering a closer emulation of human biology compared to traditional cell lines, has become indispensable for understanding disease mechanisms, advancing drug discovery, and facilitating therapeutic development.

Key Points: 
  • Primary cell culture, offering a closer emulation of human biology compared to traditional cell lines, has become indispensable for understanding disease mechanisms, advancing drug discovery, and facilitating therapeutic development.
  • Additionally, primary cell culture is playing a pivotal role in regenerative medicine, aiming to repair or replace damaged tissues and organs.
  • The growing interest and investment in regenerative medicine are propelling the growth of the primary cell culture market.
  • While the pandemic disrupted various sectors, it underscored the vital role of primary cell culture in comprehending viruses and developing treatments.

Primary Cells Market Research Report 2023: Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Health, Genetics, Science, Stem Cells, Research, COPD, Corning Inc., Prevalence, Liver, Stemcell Technologies, Haematopoiesis, Biotechnology, Heart, Bone marrow, Cancer, Lung cancer, ATCC, Merck Group, DSM-IV codes, Cell, Human, Lung, USD, Cryopreservation, Stomach cancer, Incidence, Developed country, Investment, Melanoma, Immune system, Drug discovery, Growth, Transplant, Primary cell culture, Rest, ChromeOS, Fine chemical, Renewable energy, Vaccine, Video game, Pharmaceutical industry, Hepatocyte, Human musculoskeletal system

The "Global Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • On the basis of origin, the primary cells market is divided into animal and human primary cells.
  • In 2022, the human primary cells segment accounted for the largest share of the primary cells market.
  • Based on type, the primary cells market is segmented into hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells.

Global Cell Dissociation Market Analysis 2023-2028: Non-Enzymatic Tissue Dissociation - A Lucrative Market Opportunity - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
Health, Other Health, GMP, Tissue, Connective tissue, Corning Inc., Therapy, Stemcell Technologies, Trypsin, Enzyme, ATCC, Merck Group, Research, Danaher Corporation, Certification, Becton, Dickinson and Company headquarters, Incidence, Investment, Growth, Miltenyi Biotec, Region, DNASE1L1, Fine chemical, Pharma, Papain

This report studies the cell dissociation market based on product, tissue type, application, end-user, and region.

Key Points: 
  • This report studies the cell dissociation market based on product, tissue type, application, end-user, and region.
  • The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total cell dissociation market.
  • Based on product, the cell dissociation market is segmented into enzymatic dissociation agents, non-enzymatic dissociation agents, and instruments & accessories.
  • Based on tissue type, the cell dissociation market has been segmented into connective tissue, epithelial tissue, and other tissues (muscle tissue, lung tissue, and nerve tissue).

Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE® 327 as an Intravenous Infusion Formulation

Retrieved on: 
Thursday, July 20, 2023
Volunteering, Male, Regulation of therapeutic goods, Urinary tract infection, UTI, Respiratory rate, Infection, Kidney failure, Pharmacokinetics, ECG, PEG, Therapeutic Goods Administration, ASX, Escherichia coli, FSE, Toxicity, ATCC, Kidney, Gram-negative bacteria, Female, Sepsis, Șaeș, Thermoregulation, Death, Vital signs, MD, Patient, Bacteria, Heart rate, Health, Plasma (physics), Monitoring, Safety, RCE, Medical imaging, Pharmaceutical industry, Dietary supplement, Medical device, Phosphorus, Urine, Plasma

SYDNEY Australia, July 20, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I (R327-001) study of RECCE® 327 (R327) as an intravenous (IV) infusion formulation in 80 healthy male subjects.

Key Points: 
  • We look forward to building off these results by initiating a Phase II study in patients with early-stage sepsis.
  • A total of 80 subjects were randomized in eight single-dose cohorts, and 60 subjects received R327, with 20 receiving placebo.
  • Enrolled subjects completed dosing per the protocol and completed the trial without dosing interruptions.
  • The Company is currently conducting a Phase I/II UTI clinical trial evaluating R327 IV at faster infusion rates – recently announcing its first cohort dosed, including its first female subject.

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
Intercept, Bachelor, Drug development, Therapy, Senior, Pharmacia, Virology, Biotechnology, ATCC, Viral, Pharmacia & Upjohn, ATCC (company), Doctor of Philosophy, Chemistry, Development, HBV, Management, Arbutus

“We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.

Key Points: 
  • “We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.
  • She currently serves as a board member for Lannett Company, Inc., and American Type Culture Collection (ATCC).
  • Dr. Rewolinski, commented, “This is an exciting time to join the Board of Arbutus.
  • I look forward to working with my fellow Board members to support Arbutus in its continued efforts to develop treatments for HBV and coronaviruses.”

Synthego and ATCC Enter Alliance for Cutting-Edge Gene Editing of Mammalian and Mouse Cell Lines

Retrieved on: 
Wednesday, June 28, 2023
CRISPR, Partnership, Genetic engineering, Therapy, Gene, Doctor of Philosophy, Engineering, Gene editing, ATCC, Research, Immortalised cell line, Collection, Medicine, Drug discovery, Genome, Vaccine, Pharmaceutical industry

REDWOOD CITY, Calif., June 28, 2023 /PRNewswire/ -- Synthego, a leading genome engineering company, is pleased to announce a groundbreaking partnership with ATCC, the premier non-profit global biological materials and standards resource center, to provide researchers with an extensive collection of mammalian and mouse cell lines for gene editing applications, including Express Cell Pools to increase speed to results.

Key Points: 
  • This alliance brings together Synthego's expertise in genome engineering and ATCC's renowned reputation as a trusted provider of authenticated biological materials and standards.
  • CRISPR-edited cell pools are indispensable tools for many research applications, from disease modeling to loss-of-function screens and drug discovery.
  • Synthego's Gene Engineering Platform, powered by advanced CRISPR technology, enables precise and efficient gene editing, enabling scientists to unlock the full potential of their research.
  • For more information about Synthego's innovative Cell Line Engineering and gene editing solutions, please visit www.synthego.com .

ATCC Announces New Award from BARDA to Further Support its Medical Countermeasures Clinical Studies Network

Retrieved on: 
Tuesday, June 27, 2023
Other Health, Research, Pharmaceutical, Oncology, Infectious Diseases, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Other Science, Health, United States Department of Health and Human Services, ASPR, Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Senior, HHS, Doctor of Philosophy, CSN, Human services, Public, Trial of the century, Administration for Strategic Preparedness and Response, Government, Administration, Development, Biological specimen, Collection, BARDA, Air tasking order, Safety, Medical device, Pharmaceutical industry, ATCC

As part of this award, ATCC, a member of BARDA’s Clinical Studies Network (CSN), operates the CSN’s Biological Specimen and Investigational Product (BSIP) storage facility and provides centralized services, storage and distribution of its clinical samples and investigational products across BARDA-supported studies.

Key Points: 
  • As part of this award, ATCC, a member of BARDA’s Clinical Studies Network (CSN), operates the CSN’s Biological Specimen and Investigational Product (BSIP) storage facility and provides centralized services, storage and distribution of its clinical samples and investigational products across BARDA-supported studies.
  • “Since 2020, ATCC has been a partner in BARDA’s Clinical Study Network using demonstrated best practices for the safe and secure management of biological specimens,” said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.
  • “This award is another example of our ongoing support for medical countermeasures development to protect public health and safety.”
    This task order is specific to storing biosafety level 3 (BSL-3) select agents and non-select agent materials for BARDA under the Biological Specimen and Investigational Product (BSIP) program.
  • “We look forward to continuing to build our relationship with BARDA through this task order,” said Joseph Leonelli, Ph.D., Senior Vice President, and General Manager of ATCC Federal Solutions.

Advanced Technical Career College Partnership with MedCerts Brings New Opportunities for Students

Retrieved on: 
Wednesday, June 21, 2023
Education, Health, Practice Management, Health Technology, Continuing, University, Training, Information technology, LRN, Workforce, Student, Partnership, Arm, ATCC, Stride, Inc., NYSE, Management, Nursing

Advanced Technical Career College (ATCC) has partnered with MedCerts , the innovation leader in online career training in allied health and information technology and a subsidiary of Stride, Inc .

Key Points: 
  • Advanced Technical Career College (ATCC) has partnered with MedCerts , the innovation leader in online career training in allied health and information technology and a subsidiary of Stride, Inc .
  • (NYSE: LRN), an education company that provides online and blended education programs, to offer MedCerts courses to students.
  • The new partnership diversifies the educational opportunities that ATCC offers to students and expands the reach of MedCerts’ high quality healthcare training programs.
  • “By collaborating with MedCerts, ATCC moves closer to its vision of enabling adult learners to pursue new careers or higher education without incurring lifelong debt,” said Edy Romain President/ CEO at Advanced Technical Career College.

Cultivarium Announces Collaboration with ATCC to Expand Repertoire of Microbes Available for the Bioeconomy

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Agriculture, CRISPR, GFP, Climate, Growth, ATCC, Research, Collection, Medicine, Microbiology, Vaccine

The collaboration seeks to expand the utility of ATCC's microbiology reference materials to accelerate biomanufacturing and biotechnology research and development by making more microorganisms accessible.

Key Points: 
  • The collaboration seeks to expand the utility of ATCC's microbiology reference materials to accelerate biomanufacturing and biotechnology research and development by making more microorganisms accessible.
  • And yet, today's bioeconomy relies on a handful of model microbes among the large number of species identified.
  • "Our goal is to expand the reach of ATCC's collection by making these organisms genetically tractable to the life science community.
  • Cultivarium will generate open-source protocols, data sets, and tools that will be published on the Cultivarium portal.